EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Paclitaxel- and Sirolimus-Coated Balloons Versus Drug-Eluting Stents in Coronary Artery Disease: A Comprehensive Narrative Review

Flavius-Alexandru Gherasie iD, Al Hassan Ali, Ana Maria Corzanu, Eva Catalina Costescu, Sonia-Gabriela Cornea

Life · 31.12.2025 · 16 (1) · 63

DOI: 10.3390/life16010063 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 31.12.2025. Verfasst von Flavius-Alexandru Gherasie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University of Medicine and Pharmacy "Carol Davila," 050474 Bucharest, Romania. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Medicine and Pharmacy Carol Davila.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug-coated balloons (DCBs) have emerged as an alternative to drug-eluting stents (DESs) in percutaneous coronary intervention, delivering antiproliferative drugs without leaving a permanent implant. This review provides a comparative analysis of sirolimus-coated DCBs (DCB-S), paclitaxel-coated DCBs (DCB-P), and DESs across key scenarios: de novo coronary lesions in chronic coronary syndrome (CCS), acute coronary syndromes (ACS), and in-stent restenosis (ISR). We discuss late lumen loss (LLL), target lesion/vessel revascularization (TLR/TVR), vessel patency, and major adverse cardiac events (MACE) outcomes, along with current guidelines and emerging indications for DCB-S. We also examine pharmacological differences between sirolimus and paclitaxel (mechanisms of action, tissue uptake, and healing profiles), trial methodologies, and recent innovations in DCB technology. Across stable de novo lesions (especially small vessels and high bleeding-risk patients), multiple trials show DCB-P can achieve non-inferior clinical outcomes to DES. Early data suggest newer DCB-S may likewise match DES outcomes in broader populations. In ACS, DCB-only strategies have demonstrated feasibility and safety in carefully selected lesions without heavy thrombus, with randomized studies like REVELATION (STEMI) showing non-inferior fractional flow reserve and low revascularization rates compared to DES. For ISR, DCB-P is an established Class I treatment in both BMS-ISR and DES-ISR, yielding similar or lower TLR rates than repeat stenting. DCB-S are now being evaluated as an alternative in ISR, aiming to avoid additional stent layers. Contemporary guidelines endorse DCB use in ISR and small vessels, and experts anticipate expanding indications as evidence grows. Sirolimus and paclitaxel differ in antiproliferative mechanisms and pharmacokinetics—sirolimus (cytostatic, mTOR inhibition) may offer faster endothelial recovery, whereas paclitaxel’s high lipophilicity ensures sustained arterial wall retention. Technological advances (e.g., phospholipid micro-reservoirs for sirolimus) are enhancing drug transfer and addressing prior limitations. In summary, DCB-P and DCB-S now represent viable alternatives to DES in specific scenarios, especially where “leaving nothing behind” could reduce long-term complications. Ongoing large randomized trials, such as SELUTION DeNovo, currently available as conference-presented data, together with longer-term follow-up will further clarify the optimal niches for DCB-S versus DCB-P and DES.

Schlagwörter

Stichwörter der Autor:innen

acute coronary syndromeballoon angioplastycoronary artery diseasedrug-coated balloondrug-eluting stentin-stent restenosislate lumen lossmajor adverse cardiac eventsminimal lumen diameterpaclitaxelpercutaneous coronary interventionsirolimustarget lesion revascularization

Autor:innen und Institutionen

  • Department of Cardiology, University of Medicine and Pharmacy "Carol Davila," 050474 Bucharest, Romania.
  • Emergency Clinical Hospital Dr. Bagdasar-Arseni, 050474 Bucharest, Romania.
  • Department of Cardiology, Elias University Emergency Hospital, 011461 Bucharest, Romania.

ORCID-Profile: Flavius-Alexandru Gherasie

Förderung

  • University of Medicine and Pharmacy Carol Davila

Zitieren

APA

Gherasie, F. A., Ali, A. H., Corzanu, A. M., Costescu, E. C., & Cornea, S. G. (2025). Paclitaxel- and Sirolimus-Coated Balloons Versus Drug-Eluting Stents in Coronary Artery Disease: A Comprehensive Narrative Review. Life, 16(1), 63. https://doi.org/10.3390/life16010063

Vancouver

Gherasie FA, Ali AH, Corzanu AM, Costescu EC, Cornea SG. Paclitaxel- and Sirolimus-Coated Balloons Versus Drug-Eluting Stents in Coronary Artery Disease: A Comprehensive Narrative Review. Life. 2025;16(1):63. doi:10.3390/life16010063

BibTeX
@article{Gherasie2025,
  author = {Gherasie, Flavius-Alexandru and Ali, Al Hassan and Corzanu, Ana Maria and Costescu, Eva Catalina and Cornea, Sonia-Gabriela},
  title = {Paclitaxel- and Sirolimus-Coated Balloons Versus Drug-Eluting Stents in Coronary Artery Disease: A Comprehensive Narrative Review},
  journal = {Life},
  year = {2025},
  volume = {16},
  number = {1},
  pages = {63},
  doi = {10.3390/life16010063}
}
Kostenlos starten →